Compare · CI vs VRDN
CI vs VRDN
Side-by-side comparison of The Cigna Group (CI) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 35.6x VRDN ($2.22B).
- Over the past year, CI is up 1.0% and VRDN is down 21.3% - CI leads by 22.3 points.
- CI has hit the wire 5 times in the past 4 weeks while VRDN has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Viridian Therapeutics Inc.
- Price
- $302.33+1.11%
- $19.05-2.56%
- Market cap
- $78.96B
- $2.22B
- 1M return
- +9.55%
- -13.05%
- 1Y return
- +0.96%
- -21.31%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest VRDN
- Chief Legal Officer Tousignant Jennifer sold $348,194 worth of shares (14,212 units at $24.50) and exercised 10,000 shares at a strike of $14.41, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tripuraneni Radhika exercised 40,000 shares at a strike of $13.21 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Viridian Therapeutics Inc.
- SEC Form 10-Q filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Kiselak Tomas
- SEC Form 4 filed by Director Gheuens Sarah
- SEC Form 4 filed by Director Moses Jennifer K.